上述协议签署后，杭州更好与葛航形成一致行动人关系。2025年11月14日，杭州更好与锦福源（海 南）私募基金管理合伙企业（有限合伙）（作为锦福源长弓五号私募证券投资基金管理人）（以下简 称"锦福源"）签署了《关于创业慧康科技股份有限公司的表决权委托暨一致行动协议》，约定锦福源将 其持有的公司40,000,000股股份（约占公司总股本的2.58%）对应的全部表决权委托给杭州更好行使。 上述协议签署后，杭州更好与锦福源形成一致行动人关系。上述葛航、锦福源分别将其持有的全部公司 股份对应的表决权委托给杭州更好行使，合称"表决权委托"。 根据上述协议和杭州更好出具的说明，表决权委托完成后，杭州更好将拥有公司12.64%股份对应 的全部表决权，成为公司第一大股东，杭州更好将与公司商议择机启动向特定对象发行事项（"向特定 对象发行股票"）。本次协议转让股份过户后，杭州更好拟向公司提名四名非独立董事、两名独立董事 人选（"董事会改选"）。无论公司是否完成向特定对象发行股票事项，若杭州更好提名的上述董事全部 当选且占公司董事会席位的半数以上，将导致公司控制权变更，杭州更好成为公司的控股股东。为确保 本次权益变动过渡期间公司业 ...

根据上述协议和杭州更好出具的说明，表决权委托完成后，杭州更好将拥有公司12.64%股份对应的全 部表决权，成为公司第一大股东，杭州更好将与公司商议择机启动向特定对象发行事项("向特定对象发 行股票")。本次协议转让股份过户后，杭州更好拟向公司提名四名非独立董事、两名独立董事人选("董 事会改选")。无论公司是否完成向特定对象发行股票事项，若杭州更好提名的上述董事全部当选且占公 司董事会席位的半数以上，将导致公司控制权变更，杭州更好成为公司的控股股东。为确保本次权益变 动过渡期间公司业务经营的连续性及核心管理和技术团队的稳定性，转让方、受让方及公司将就具体实 施方案进行磋商。 2025年11月12日，杭州更好与公司第一大股东、持股5%以上股东葛航签署了《股份转让协议》，约定 葛航将通过协议转让的方式向杭州更好转让公司96,525,096股股份(约占公司总股本的6.23%)，每股转让 价格为人民币5.18元("协议转让")，不低于公司前一交易日(2025年11月7日)股票收盘价的80%；同日， 杭州更好与葛航签署了《关于创业慧康科技股份有限公司的表决权委托暨一致行动协议》，约定葛航将 持有的公司155,780,2 ...

Group 1 - Company Shikong Technology plans to reduce its holdings by no more than 0.29% of its shares, equivalent to 29,070 shares, starting from December 8, 2025 [1] - Company Rongbai Technology has been designated as the first supplier of sodium-ion battery cathode materials for CATL, with a commitment to purchase at least 60% of its total procurement volume annually [1] - Company Xinnong plans to reduce its holdings by no more than 300,000 shares, representing 0.19% of its total shares, within three months from 15 trading days after the announcement [1][2] Group 2 - Company Zhenai Meijia's controlling shareholder has signed an agreement for share transfer, with no asset restructuring plans for the next 12 months [1] - Company Guochuang High-tech plans to reduce its holdings by no more than 1% of its shares, equivalent to 9,163,300 shares, starting from December 9, 2025 [1] - Company Jiuyang clarifies that it does not engage in food and beverage businesses, focusing solely on small household appliances [6][7] Group 3 - Company Furui's subsidiary has reported a net loss of approximately 30.32 million yuan in the first three quarters, with no expansion plans due to uncertainties in the lithium battery industry [8] - Company Annada has elected Li Chongjun as the chairman of its board [10] - Company Maihe's chairman is under investigation and has been placed under detention [12] Group 4 - Company Luoping Zinc Electric's subsidiary has resumed production at its Jinpo lead-zinc mine after obtaining new mining licenses [13] - Company Hengxing Technology has obtained mining rights for its Longtoushan gold mine [14] - Company Qianli Technology plans to reduce its holdings by no more than 2% of its shares, equivalent to 90,422,000 shares, starting from December 8, 2025 [15] Group 5 - Company Fudan Microelectronics' largest shareholder will change to Guosheng Investment after a share transfer agreement [16] - Company Zhongsheng Pharmaceutical is advancing several clinical trials for innovative drug projects, which carry uncertainties regarding approval and market competition [18] - Company Gaoling Information's shareholders plan to collectively reduce their holdings by no more than 1.49% of the shares [20] Group 6 - Company Chuangye Huikang is in the process of planning a change of control, with uncertainties regarding the implementation of related agreements [21] - Company GAC Group has appointed He Xianqing as the new general manager, succeeding Feng Xingya [22] - Company Heshun Petroleum plans to acquire at least 34% of Kuixin Technology and control 51% of its voting rights [23][24] Group 7 - Company Yifeng Pharmacy's executives plan to reduce their holdings by a total of no more than 213,900 shares due to personal financial needs [26][27]

于完成收购事项及投票权委托后，本公司将持有目标公司股权(表决权)约12.64%。于目标公司董事会组 成调整后，目标公司董事会将由十一名董事组成，超过半数的董事会成员由买方提名。因此，紧随完成 收购事项、投票权委托及根据股份转让协议所规定的目标公司董事会组成调整后，本公司将于目标公司 董事会中拥有大多数董事席位，并将能够对通过目标公司董事会决议案施加重大影响。目标公司被视为 本公司的附属公司，目标公司的财务业绩将于本集团的综合财务报表综合入账。 本次收购创业慧康控制权，是华检医疗在国家战略指引下，基于对AI医疗产业趋势的深刻洞察，依托 自身独特的"K×A"智能资本模式，对一家拥有深厚积淀与创新活力的行业领军企业进行的战略性投资。 通过此次并购及后续的全面赋能与深度融合，华检医疗将与创业慧康携手，共同开啓中国"AI+医疗"的 新篇章，不仅为双方股东创造持续且丰厚的回报，亦将为推动中国医疗健康事业的进步、服务国家发展 大局贡献坚实力量。 华检医疗(01931)发布公告，于2025年11月12日，本公司(买方)与卖方订立股份转让协议及第一份投票权 委托协议，本公司已有条件同意收购，而卖方已有条件同意出售目标公司创业慧 ...

Group 1: Share Transfer Announcements - Fudan Microelectronics (688385) announced that Guosheng Investment will acquire 12.99% of its shares from Fuxin Fangao for 5.144 billion yuan, making Guosheng the largest shareholder [3][4][5] - Heshun Petroleum's actual controllers plan to transfer 6% of the company's shares to Chen Wanyi for a total price of 236.5 million yuan [3][6] - Chuangyue Health is undergoing a control change, with a significant share transfer agreement signed, which will lead to a new major shareholder [3][8][10] Group 2: Financial Performance and Projections - Fudan Microelectronics reported Q3 2025 revenue of 1.186 billion yuan, a year-on-year increase of 33.28% and a quarter-on-quarter increase of 24.68%, with a net profit of 137 million yuan, up 72.69% year-on-year [5] - Heshun Petroleum is acquiring at least 34% of Kuixin Technology, with a total valuation of no more than 1.588 billion yuan, and expects to control 51% of the voting rights [6][7] - Kuixin Technology has revenue commitments from 2025 to 2028, with annual revenues projected to be no less than 300 million yuan in 2025, increasing to 750 million yuan by 2028 [7] Group 3: Strategic Moves and Partnerships - The share transfer of Fudan Microelectronics is part of a strategy to enhance collaboration with Shanghai's state-owned assets in the semiconductor sector [4][5] - Heshun Petroleum's acquisition of Kuixin Technology aims to optimize its share structure and bind key management personnel to performance commitments [6][7] - Chuangyue Health's control change involves a strategic partnership with Hangzhou Better Investment, which will lead to a significant shift in the company's governance [8][9][10]

Group 1: Fudan Microelectronics Share Transfer - Fudan Microelectronics announced that Guosheng Investment will acquire 12.99% of its shares from Fuxin Vango for 5.144 billion yuan, making Guosheng the largest shareholder [1][3][4] - The share transfer price is set at 48.20 yuan per share, and after the transfer, Fuxin Vango will no longer hold any shares in Fudan Microelectronics [3][4] - Fudan Microelectronics will remain without a controlling shareholder, and the strategic cooperation with Fudan University will continue [3][4] Group 2: Heshun Petroleum Share Transfer - Heshun Petroleum's actual controllers plan to transfer 6% of the company's shares to Chen Wanyi for a total of 236.5 million yuan, with a share price of 22.932 yuan [2][5] - After the transfer, the controlling shareholders will hold 60.58% of the company, while Chen Wanyi will hold 6% [5] - The transfer is part of Heshun Petroleum's strategy to acquire control of Kuixin Technology, with a total transaction value not exceeding 540 million yuan [5][6] Group 3: Chuangyi Huikang Control Change - Chuangyi Huikang announced a planned change in control, with a share transfer agreement signed for 6.23% of the company's shares at a price of 5.18 yuan per share [7][8] - Following the transfer, the new entity, Hangzhou Better, will hold 12.64% of the voting rights, potentially becoming the largest shareholder [8][9] - If the proposed board members are elected, it could lead to a change in control of Chuangyi Huikang [8][9]

Group 1 - The Ministry of Education and the Ministry of Culture and Tourism issued a warning regarding studying and traveling in Japan due to rising safety risks for Chinese citizens [2] - The warning highlights a significant decline in flight volumes from mainland China to Japan [2] Group 2 - The State Council meeting emphasized "promoting consumption and stabilizing investment," indicating potential new rounds of interest rate cuts and reserve requirement ratio reductions [3] - The focus is shifting towards achieving a dynamic balance between supply and demand, with an emphasis on consumption upgrades leading to industrial upgrades [3] Group 3 - The A-share IPO market has seen a significant increase in acceptance and review speed, with IPO acceptance volume rising over 400% year-on-year from January to October [4] - The Beijing Stock Exchange has become a primary platform for IPO applications, injecting new vitality into the market [4] Group 4 - Huawei is set to unveil breakthrough AI technologies aimed at improving computing resource utilization efficiency, targeting a significant increase from the industry average of 30%-40% to 70% [5][6] - This technology aims to unify resource management across various computing hardware, enhancing support for AI training and inference [6] Group 5 - Bitcoin has erased over 30% of its gains for the year, dropping below $93,714, following a decline in enthusiasm for the Trump administration's pro-cryptocurrency stance [7] - The price peaked at $126,251 on October 6, but subsequent market reactions led to a significant downturn [7] Group 6 - Multiple A-share companies have disclosed equity transfer matters, with Fudan Microelectronics announcing a transfer of 12.99% of its shares for 5.144 billion yuan, making the acquirer the largest shareholder [8][12] - Other companies, such as HeShun Petroleum and Chuangye Huikang, are also involved in significant equity transfers and control changes [8][12] Group 7 - The demand for energy storage has surged, increasing over 300%, driven by the dual carbon goals and the rising penetration of renewable energy [9] - The market has seen accelerated demand release following policy changes that removed mandatory storage requirements [9] Group 8 - Several companies are facing risks due to rapid stock price increases, with announcements from Pingtan Development and others warning of potential irrational speculation [10] - The stock of HeFu China is set to be suspended for review following a significant price surge [10] Group 9 - The solid-state battery sector has gained attention, but major players like CATL are still focusing on liquid batteries due to the high commercialization challenges of solid-state technology [11] Group 10 - The stock of Tianfu Communication is undergoing a share transfer process, with a significant portion of shares being transferred to meet funding needs [13] - The transfer is structured to ensure that the new investor has the capacity to manage the associated risks [13]

Group 1 - Chinese scientists have made a breakthrough in the treatment of neurological diseases by revealing the key role of the formyl peptide receptor 1 (FPR1) pathway in central nervous system inflammation and degeneration, leading to the development of a new drug molecule with clinical application potential for diseases like multiple sclerosis [1] - The research was conducted by a team led by Academician Shi Fudong from Tianjin Medical University General Hospital and published in the international journal "Science" [1] Group 2 - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, received approval from the National Medical Products Administration for clinical trials of an oral small molecule growth hormone, GS3-007a, aimed at treating children with growth retardation due to endogenous growth hormone deficiency [2] - This product is significant as there are currently no similar products on the market in China, and its approval could address unmet clinical needs [2] - The oral small molecule growth hormone is expected to improve convenience and compliance compared to existing subcutaneous injection options, but its market impact will depend on the verification of efficacy and long-term safety in subsequent clinical trials [2] Group 3 - Hehe China reported that its stock experienced twelve limit-up days out of fourteen trading days from October 28 to November 14, with a cumulative increase of 256.29%, significantly exceeding the industry and Shanghai Composite Index performance [3] - The company has warned of risks associated with market sentiment and irrational speculation, indicating a potential for rapid price declines [3] - Due to the excessive speculation, the company has applied for a trading suspension starting November 17, with an expected duration of no more than three trading days [3] Group 4 - Chuangye Huikang announced that its largest shareholder, Ge Hang, is in discussions regarding a change of control with Hangzhou Genghao Zhituo Management Consulting Partnership, with the process still ongoing and uncertain [4] - The company plans to resume trading on November 17, following the announcement of the control change discussions [4] - The healthcare information industry is becoming increasingly competitive, and a successful control change could introduce new resources and management strategies, although significant uncertainties remain [4]

同时，葛航将1.56亿股股份(约占公司总股本的10.06%)的表决权不可撤销地全权委托给杭州更好行使。 11月14日，杭州更好与锦福源(海南)私募基金管理合伙企业签署表决权委托暨一致行动协议，锦福源将 其持有的公司4000万股股份(约占公司总股本的2.58%)对应的全部表决权委托给杭州更好行使。表决权 委托完成后，杭州更好将拥有公司12.64%股份对应的全部表决权，成为公司第一大股东，杭州更好将 与公司商议择机启动向特定对象发行事项。 创业慧康（300451）(300451.SZ)发布公告，2025年11月12日，公司股东葛航与杭州更好智投管理咨询 合伙企业(有限合伙)签署股份转让协议，葛航将通过协议转让方式向杭州更好转让公司9652.51万股股份 (约占公司总股本的6.23%)，每股转让价格为人民币5.18元。 此次协议转让事项尚需提交相关部门审核及办理过户手续。公司筹划控制权变更事项仍在进行中，协议 转让、董事会改选、向特定对象发行股票等事项能否最终实施完成及实施结果尚存在不确定性。公司股 票将于2025年11月17日开市起复牌。 ...

此次协议转让事项尚需提交相关部门审核及办理过户手续。公司筹划控制权变更事项仍在进行中，协议 转让、董事会改选、向特定对象发行股票等事项能否最终实施完成及实施结果尚存在不确定性。公司股 票将于2025年11月17日开市起复牌。 同时，葛航将1.56亿股股份(约占公司总股本的10.06%)的表决权不可撤销地全权委托给杭州更好行使。 11月14日，杭州更好与锦福源(海南)私募基金管理合伙企业签署表决权委托暨一致行动协议，锦福源将 其持有的公司4000万股股份(约占公司总股本的2.58%)对应的全部表决权委托给杭州更好行使。表决权 委托完成后，杭州更好将拥有公司12.64%股份对应的全部表决权，成为公司第一大股东，杭州更好将 与公司商议择机启动向特定对象发行事项。 创业慧康(300451.SZ)发布公告，2025年11月12日，公司股东葛航与杭州更好智投管理咨询合伙企业(有 限合伙)签署股份转让协议，葛航将通过协议转让方式向杭州更好转让公司9652.51万股股份(约占公司总 股本的6.23%)，每股转让价格为人民币5.18元。 ...